Cutaneous Squamous Cell Carcinoma: Clinical Trials

26 trials for Cutaneous Squamous Cell Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 recruiting, 6 completed, 5 terminated, 4 active not recruiting. 26 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 126Recruiting 7, Completed 6, Terminated 5, Active not recruiting 4, Unknown 2, Withdrawn 2
Phase 26Active not recruiting 2, Recruiting 2, Completed 1, Terminated 1

Follow Cutaneous Squamous Cell Carcinoma: new trials by email Literature Review of Cutaneous Squamous Cell Carcinoma trials Research Report on Cutaneous Squamous Cell Carcinoma

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1 / Phase 2RecruitingInduPro, Inc.1322026-07-082026-09-03
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
tolododekin alfa, Cemiplimab - Advanced Solid Tumor, Cutaneous Tumor
Phase 1RecruitingAnkyra Therapeutics, Inc972024-01-192026-03-06
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
Microneedle Array Doxorubicin (MNA-D) - Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingFalo, Louis, MD482023-09-132026-04-09
Cemiplimab/Peg-Interferon-α in Advanced CSCC
Cemiplimab-Rwlc, PEG-IFN alfa-2a - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma
Phase 1WithdrawnBaptist Health South Florida2023-07-012023-08-09
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
Phase 1RecruitingMemorial Sloan Kettering Cancer Center562023-05-042026-08-12
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Phase 1Active not recruitingUniversity of Southern California142023-01-092026-06-18
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2Active not recruitingImmunitas Therapeutics672022-11-282025-10-16
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
MEM-288 Intratumoral Injection, Nivolumab, Docetaxel - Solid Tumor, Advanced Cancer
Phase 1RecruitingMemgen, Inc.402022-04-212026-06-11
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
RM-1995, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Phase 1WithdrawnRakuten Medical, Inc.2022-03-242023-04-19
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
Cemiplimab-Rwlc - Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Phase 1RecruitingH. Lee Moffitt Cancer Center and Research Institute362021-10-222026-06-25
A Beta-only IL-2 ImmunoTherapY Study
MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor
Phase 1 / Phase 2Active not recruitingMedicenna Therapeutics, Inc.1602021-08-272026-10-30
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
IFx-Hu2.0 - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Phase 1CompletedTuHURA Biosciences, Inc.52021-06-102024-08-02
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
INCB099318 - Advanced Solid Tumors, MSI-H/dMMR Tumors
Phase 1TerminatedIncyte Corporation1052021-03-262025-10-16
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
GEN-011, IL-2, Fludarabine - Melanoma, Non-small Cell Lung Cancer
Phase 1TerminatedGenocea Biosciences, Inc.492020-11-112022-07-15
Cemiplimab in AlloSCT/SOT Recipients With CSCC
Cemiplimab, Everolimus, Sirolimus - Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Phase 1 / Phase 2CompletedDana-Farber Cancer Institute122020-11-032025-04-23
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
Drug: SL-172154 - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Phase 1TerminatedShattuck Labs, Inc.52020-09-172025-02-24
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
INCB099280 - Advanced Solid Tumor, MSI-H/dMMR Tumors
Phase 1CompletedIncyte Corporation1822020-09-042025-07-14
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
TBio-6517, Pembrolizumab - Solid Tumor, Microsatellite Stable Colorectal Cancer
Phase 1TerminatedTurnstone Biologics, Corp.272020-06-022025-04-23
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
BCA101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal
Phase 1RecruitingBicara Therapeutics4732020-06-012026-10-06
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
IFx-Hu2.0 - Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Phase 1CompletedTuHURA Biosciences, Inc.232020-03-032024-09-23

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Carcinoma, Merkel Cell (11)  ·  Squamous Cell Carcinoma of Head and Neck (10)  ·  Carcinoma, Basal Cell (8)  ·  Melanoma (8)  ·  Skin Neoplasms (7)  ·  Neoplasm Metastasis (6)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Carcinoma, Renal Cell (5)  ·  Carcinoma, Squamous Cell (5)  ·  Head and Neck Neoplasms (5)  ·  Neoplasms (5)  ·  Carcinoma, Transitional Cell (4)  ·  Uterine Cervical Neoplasms (4)  ·  Anus Neoplasms (3)  ·  Colorectal Neoplasms (3)

Broader conditions

Neoplasms by Histologic Type (23)  ·  Neoplasms, Glandular and Epithelial (23)  ·  Carcinoma (22)  ·  Neoplasms (19)  ·  Neoplasms by Site (19)  ·  Skin Diseases (13)  ·  Skin and Connective Tissue Diseases (13)  ·  Adenocarcinoma (12)  ·  DNA Virus Infections (12)  ·  Infections (12)  ·  Neoplasms, Germ Cell and Embryonal (12)  ·  Neoplasms, Nerve Tissue (12)  ·  Neuroectodermal Tumors (12)  ·  Neuroendocrine Tumors (12)  ·  Tumor Virus Infections (12)

Interventions

pembrolizumab (6)  ·  cemiplimab (3)  ·  Interleukin-2 (2)  ·  Capecitabine (1)  ·  Cetuximab (1)  ·  Coat Protein Complex I (1)  ·  Cyclophosphamide (1)  ·  Docetaxel (1)  ·  Doxorubicin (1)  ·  Everolimus (1)  ·  Glatiramer Acetate (1)  ·  HMPL-013 (1)  ·  Nivolumab (1)  ·  Prednisone (1)  ·  Radiation (1)

Sponsors

Incyte Corporation (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  TuHURA Biosciences, Inc. (2)  ·  Ankyra Therapeutics, Inc (1)  ·  Baptist Health South Florida (1)  ·  Bicara Therapeutics (1)  ·  Checkpoint Therapeutics, Inc. (1)  ·  Dana-Farber Cancer Institute (1)  ·  Falo, Louis, MD (1)  ·  Genocea Biosciences, Inc. (1)  ·  Genzada Pharmaceuticals USA, Inc. (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Immunitas Therapeutics (1)  ·  InduPro, Inc. (1)  ·  Medicenna Therapeutics, Inc. (1)

Countries

United States (24)  ·  Australia (5)  ·  Canada (4)  ·  Belgium (2)  ·  France (2)  ·  South Korea (2)  ·  Spain (2)  ·  Denmark (1)  ·  Finland (1)  ·  Ireland (1)  ·  Japan (1)  ·  Netherlands (1)  ·  New Zealand (1)  ·  Norway (1)  ·  Poland (1)

Top investigators

Lara Dunn, MD (2)  ·  Ahmad Tarhini, MD, PhD (1)  ·  Andreas Saltos, MD (1)  ·  Andrew S Brohl, MD (1)  ·  Arash Yavari, MBBS (1)  ·  Brian Gastman, MD (1)  ·  Fumito Ito, MD (1)  ·  Glenn J Hanna, MD (1)  ·  Guilherme Rabinowits, M.D. (1)  ·  Ines Verdon, MD (1)  ·  Joaquina Baranda, MD (1)  ·  Joseph Elassal, MD, MBA (1)  ·  Kathryn Gazarik (1)

Results publications

PMID 42580817, PMID 33477979, PMID 35276694, PMID 36821617, PMID 37848259, PMID 38252908, PMID 38758815, PMID 40230575, PMID 41022754, PMID 42102329

NIH funding

2019 (2), 2023 (1), P50CA254865 (1)